ScholarIQanswers from OpenAlex & ORCID
Anthony W. Tolcher
ResearcherPublications, citations & collaboration network
Anthony W. Tolcher is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Anthony W. Tolcher have?
ScholarIQindexed works
Anthony W. Tolcher has 947 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Anthony W. Tolcher have?
ScholarIQcitation count
Anthony W. Tolcher has 24,458 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Anthony W. Tolcher?
ScholarIQh-index
Anthony W. Tolcher has an h-index of 76 in OpenAlex.
What is the i10-index of Anthony W. Tolcher?
ScholarIQi10-index
Anthony W. Tolcher has an i10-index of 269 in OpenAlex.
What is the ORCID of Anthony W. Tolcher?
ScholarIQorcid
The ORCID for Anthony W. Tolcher is on the source record.
What is the OpenAlex record for Anthony W. Tolcher?
ScholarIQopenalex
The OpenAlex for Anthony W. Tolcher is on the source record.
What are the most-cited papers on Anthony W. Tolcher?
ScholarIQmost cited works
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan W. Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, John Hilton, Aejaz Nasir, Richard P. Beckmann, Andrew E. Schade, Angie D. Fulford, Tuan S. Nguyen, Ricardo Martínez, Palaniappan Kulanthaivel, Lily Q. Li, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Geoffrey I. Shapiro
Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Anthony W. Tolcher, Wells A. Messersmith, Stanislaw M. Mikulski, Kyriakos P. Papadopoulos, Eunice L. Kwak, Darlene Gibbon, Amita Patnaik, Gerald S. Falchook, Arvind Dasari, Geoffrey I. Shapiro, John F. Boylan, Zhi-Xin Xu, Ka Wang, Astrid Koehler, James Song, Steven A. Middleton, Jonathan Deutsch, Mark DeMario, Razelle Kurzrock, Jennifer J. Wheler
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Amita Patnaik, Leonard J. Appleman, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, Glen J. Weiss, Jasgit C. Sachdev, Manpreet Chadha, Maddie Fulk, Samuel Ejadi, James M. Mountz, Michael T. Lotze, Frederico G. S. Toledo, Edward Chu, Michael Jeffers, Carol E. Peña, Chenjing Xia, Stefanie Reif, Isabelle Genvresse, Ramesh K. Ramanathan
Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
David W. Craig, Joyce O’Shaughnessy, Jeffrey Kiefer, Jessica Aldrich, Shripad Sinari, Tracy M. Moses, Shukmei Wong, Jennifer Dinh, Alexis Christoforides, Joanne L. Blum, Cristi L. Aitelli, Cynthia R. Osborne, Tyler Izatt, Ahmet Kurdoglu, Angela Baker, Julie Koeman, Cátálin Bárbácioru, Onur Sakarya, Francisco M. De La Vega, Asim Siddiqui, Linh Hoang, Paul R. Billings, Bodour Salhia, Anthony W. Tolcher, Jeffrey M. Trent, Spyro Mousses, Daniel D. Von Hoff, John D. Carpten
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin, Anthony J. Olszanski, Anthony W. Tolcher, Gataree Ngarmchamnanrith, Erik Rasmussen, Benny Amore, Dirk Nagorsen, John S. Hill, Joe Stephenson